The submission represents Angion Biomedica, a company that ceased independent operations in June 2023 following a reverse merger with Elicio Therapeutics after key clinical trials failed. The submission contains significant 'red flags' including demonstrably false claims of traction ('most people have used my product') and audience reach ('everyone'), while the actual company's drugs never reached the market. The financial data provided (market cap $30M) reflects the company's valuation just prior to its dissolution, confirming the project is effectively defunct and the submission is deceptive or low-quality.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline